A Phase II Multicenter, Randomized, Double-blind Study of Apatinib Combined With Paclitaxol Versus Placebo With Paclitaxol as Second Line Therapy for Advanced Gastric / Esophagogastric Junction Adenocarcinoma With Peritoneal Metastasis.
Phase of Trial: Phase II
Latest Information Update: 16 May 2017
At a glance
- Drugs Apatinib (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 16 May 2017 New trial record